Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:APEN

Apollo Endosurgery (APEN) Stock Price, News & Analysis

Apollo Endosurgery logo

About Apollo Endosurgery Stock (NASDAQ:APEN)

Key Stats

Today's Range
N/A
50-Day Range
$9.87
$10.00
52-Week Range
N/A
Volume
1.66 million shs
Average Volume
1.43 million shs
Market Capitalization
$579.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, the OverStitch Sx Endoscopic Suturing System, and the Orbera Intragastric Balloon System. Its products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal conditions including closure of acute perforations and chronic fistulas, inadvertent perforation of the GI tract, tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon, the treatment of swallowing disorders, esophageal stent fixation, and obesity. The company was founded by Christopher J. Gostout and Dennis L. McWilliams in 2005 and is headquartered in Austin, TX.

Receive APEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apollo Endosurgery and its competitors with MarketBeat's FREE daily newsletter.

APEN Stock News Headlines

Apollo Pipes Ltd 531761
Financial Prophecy
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
APEN Apollo Endosurgery, Inc.
See More Headlines

APEN Stock Analysis - Frequently Asked Questions

Apollo Endosurgery, Inc. (NASDAQ:APEN) released its quarterly earnings data on Sunday, October, 31st. The biotechnology company reported ($0.23) EPS for the quarter, beating analysts' consensus estimates of ($0.28) by $0.05. The biotechnology company had revenue of $16.35 million for the quarter, compared to analysts' expectations of $16.20 million. Apollo Endosurgery had a negative trailing twelve-month return on equity of 89.48% and a negative net margin of 51.84%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Apollo Endosurgery investors own include Pfizer (PFE), Novavax (NVAX), NVIDIA (NVDA), Ocugen (OCGN), Canopy Growth (CGC), Inovio Pharmaceuticals (INO) and Meta Platforms (META).

Company Calendar

Last Earnings
10/31/2021
Today
11/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:APEN
Employees
202
Year Founded
N/A

Profitability

Net Income
$-39,840,000.00
Pretax Margin
-51.08%

Debt

Sales & Book Value

Annual Sales
$76.86 million
Book Value
$0.69 per share

Miscellaneous

Free Float
47,943,000
Market Cap
$579.72 million
Optionable
Not Optionable
Beta
2.31

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

This page (NASDAQ:APEN) was last updated on 11/22/2024 by MarketBeat.com Staff
From Our Partners